A Randomized, Double-Blind, Placebo-Controlled Trial of a Selective, Oral Sphingosine 1-Phosphate (S1P) Receptor Modulator, Etrasimod (APD334), in Moderate to Severe Ulcerative Colitis (UC): Results From the OASIS Study

Sandborn William J.; Peyrin-Biroulet Laurent; Trokan Luba; Zhang Jinkun; Kuhbacher Tanja; Chiorean Michael; Lee Scott D.; Vermeire Severine; Yacyshyn Bruce; Naik Snehal; Klassen Preston; Panes Julian

首页> 外文期刊>The American Journal of Gastroenterology >A Randomized, Double-Blind, Placebo-Controlled Trial of a Selective, Oral Sphingosine 1-Phosphate (S1P) Receptor Modulator, Etrasimod (APD334), in Moderate to Severe Ulcerative Colitis (UC): Results From the OASIS Study

【24h】

A Randomized, Double-Blind, Placebo-Controlled Trial of a Selective, Oral Sphingosine 1-Phosphate (S1P) Receptor Modulator, Etrasimod (APD334), in Moderate to Severe Ulcerative Colitis (UC): Results From the OASIS Study

机译：选择性口服鞘氨酸1-磷酸（S1P）受体调节剂，eTraasimod（APD334），中度至重度溃疡性结肠炎（UC）的随机，双盲，安慰剂对照试验：来自OASIS研究的结果

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《The American Journal of Gastroenterology》 |2018年第2期|共2页
作者
Sandborn William J.; Peyrin-Biroulet Laurent; Trokan Luba; Zhang Jinkun; Kuhbacher Tanja; Chiorean Michael; Lee Scott D.; Vermeire Severine; Yacyshyn Bruce; Naik Snehal; Klassen Preston; Panes Julian;
展开▼
作者单位

Univ Calif San Diego La Jolla CA 92093 USA;

Univ Lorraine Univ Hosp Nancy Nancy Lorraine France;

Arena Pharmaceut San Diego CA USA;

Arena Pharmaceut San Diego CA USA;

Asklepio Westklinikum Hamburg Germany;

Virginia Mason Med Ctr Seattle WA 98101 USA;

Univ Washington Seattle WA 98195 USA;

Univ Hosp Leuven Leuven Brussels Hoofds Belgium;

Univ Cincinnati Cincinnati OH USA;

Arena Pharmaceut San Diego CA USA;

Arena Pharmaceut San Diego CA USA;

Hosp Clin Barcelona IDIBAPS CIBERehd Barcelona Catalonia Spain;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献

1. A Randomized, Double-Blind, Placebo-Controlled Trial of a Selective, Oral Sphingosine 1-Phosphate (S1P) Receptor Modulator, Etrasimod (APD334), in Moderate to Severe Ulcerative Colitis (UC): Results From the OASIS Study [J] . Sandborn William J., Peyrin-Biroulet Laurent, Trokan Luba, The American Journal of Gastroenterology . 2018,第Suppla2期

机译：选择性口服鞘氨酸1-磷酸（S1P）受体调节剂，eTraasimod（APD334），中度至重度溃疡性结肠炎（UC）的随机，双盲，安慰剂对照试验：来自OASIS研究的结果
2. Safety and Efficacy of Long-Term Treatment with Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis: Touchstone Extension [J] . Sandborn William J., Feagan Brian, DHaens Geert, The American Journal of Gastroenterology . 2016,第Suppla1期

机译：口服S1P受体调节剂Ozanimod在中度至重度溃疡性结肠炎中长期治疗的安全性和有效性：试金石延伸
3. Etrasimod, an oral, selective sphingosine 1-phosphate receptor modulator improves skin inflammation in a contact hypersensitivity dermatitis model [J] . Crosby C. M., Komori H. K., Adams J. W. The Journal of investigative dermatology. . 2019,第9Suppla2期

机译：eTraasimod，口服，选择性鞘氨酸1-磷酸受体调节剂改善了接触过敏皮炎模型中的皮肤炎症
4. MULTI-CENTER, PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED STUDY OF ORAL TOCERANIB PHOSPHATE (PALLADIATM, SU11654), A RECEPTOR TYROSINE KINASE INHIBITOR, FOR THE TREATMENT OF DOGS WITH RECURRENT MAS [C] . Cheryl L London, Carolyn J Henry, Anthony W Rusk, Annual conference of the Veterinary Cancer Society . 2008

机译：多中心，安慰剂对照，双盲，随机研究口服Toceranib磷酸盐（Palladia TM，SU11654），受体酪氨酸激酶抑制剂，用于治疗经常性MAS的狗
5. A Multicentre Double-Blind Placebo-Controlled Parallel-Group Study to Evaluate the Efficacy Safety and Tolerability of the S1P Receptor Agonist KRP203 in Patients with Moderately Active Refractory Ulcerative Colitis [O] . Heinfried H. Radeke, Jürgen Stein, Gert Van Assche, 2020

机译：多环境双盲安慰剂控制并行组研究以评估S1P受体激动剂KRP203在具有中度活性难治性溃疡性结肠炎患者中的疗效安全性和耐受性
6. OP024. A randomized, double-blind, placebo-controlled induction trial of an oral S1P receptor modulator (RPC1063) in moderate to severe Ulcerative Colitis: Results of the TOUCHSTONE study [O] . 2015

机译：OP024。口腔S1P受体调节剂（RPC1063）中度至重度溃疡性结肠炎的随机，双盲，安慰剂对照诱导试验：TRANGSTONE研究的结果

A Randomized, Double-Blind, Placebo-Controlled Trial of a Selective, Oral Sphingosine 1-Phosphate (S1P) Receptor Modulator, Etrasimod (APD334), in Moderate to Severe Ulcerative Colitis (UC): Results From the OASIS Study

著录项

引文网络

相似文献

相关主题

期刊订阅